Tag:
Shantha
Latest Headlines
Latest Headlines
Report: Big Pharma finds Indian collaborations costly
Big Pharma is getting bitten by its deals with Indian generics-makers. One recent example, of course, is Japan's Daiichi Sankyo, which last month felt tremors from Indian unit Ranbaxy as the latter
Sanofi's Shan5 vaccine to restart in 2013
The year 2013 still appears correct for Sanofi's ( $SNY ) relaunch of its Shantha Biotech unit's Shan5 pentavalent vaccine, sidelined in 2010 by the World Health Organization because of a white residue
Sanofi's Viehbacher sees green lights ahead for Shantha
Admitting "a setback" with its Shantha acquisition after the World Health Organization recalled and destroyed the SHAN5 vaccine in May 2010, Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) says he remains
Pharma deal-making minimizes manufacturing
Brand recognition outweighs manufacturing risk in Big Pharma thinking when it comes to growth by deal-making. In fact, "Brand acquisitions typically help buyers avoid any manufacturing risks." So
